|
IL272935D0
|
|
New use of dextran sulfate
|
|
SE1950746A1
|
|
Allogenic car-t cell therapy
|
|
SE1950292A1
|
|
Treatment efficiency evaluation
|
|
US2021060057A1
|
|
New use of dextran sulfate
|
|
WO2018212708A1
|
|
Treatment of glaucoma
|
|
CA3063851A1
|
|
Treatment of glaucoma
|
|
SE1551050A1
|
|
Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis
|
|
WO2015190989A1
|
|
The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject
|
|
CA2951686A1
|
|
The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenesis in a subject
|
|
SE1451349A1
|
|
New dextran sulfate
|
|
SE1451120A1
|
|
Use of dextran sulfate for inducing angiogenesis
|
|
SE1350584A1
|
|
Dextran sulfate for cell mobilization
|
|
WO2012008908A1
|
|
Cell therapy
|
